Intensive chemotherapy combined with second- or third-generation tyrosine kinase inhibitors improves survival in patients ...

The cost of SARMs can vary depending on the supplier, dosage, and cycle length. Typically, SARMs range from $80 to $200 per ...

Nurix Therapeutics Inc. (NRIX) presented positive clinical data from its ongoing Phase 1a/1b clinical trial of NX-5948, an orally ...

The study found that the price tag for the second-generation Bruton tyrosine kinase inhibitor would need to be reduced by 30% ...

The Tyrosine Protein Kinase JAK1 pipeline drugs market research report outlays comprehensive information on the Tyrosine Protein Kinase JAK1 targeted therapeutics, complete with analysis by ...

Investigators say adding RNA interference (RNAi) therapy to current treatment modalities may improve outcomes in patients ...

Exelixis is advancing its pipeline with zanalintinib and XB010, exploring new avenues in oncology beyond its cabozantinib ...

Cyrus M. Khan, MD, highlights some of the most recent and significant advancements in chronic lymphocytic leukemia treatment.

Researchers at the Weizmann Institute have created a composite plastic that degrades easily using bacteria and is cheap and ...

Researchers leading the SWOG S1712 clinical trial have found that adding ruxolitinib to standard tyrosine kinase inhibitor (TKI) treatment for patients with chronic-phase chronic myeloid leukemia ...

Tyrosine, a non-essential amino acid, is vital for the production of neurotransmitters like dopamine, norepinephrine, and epinephrine. These neurotransmitters play an essential part in regulating ...